MEPS urge EU action to combat "biopiracy"

15 January 2013

The European Union must combat the "biopiracy" of multinationals that exploit plants with medicinal properties and traditional remedies originating from developing countries but fail to share the profits with indigenous peoples, say Members of the European Parliament (MEPs) in a resolution adopted by a show of hands on Tuesday at a plenary session.

Biopiracy - the practice of patenting and marketing the use of traditional knowledge and genetic resources of indigenous peoples without authorization from source countries - can impede the economic progress of developing countries and runs counter to EU development policy goals, says the resolution, which notes that 70% of the world’s poor depend directly on biodiversity for their survival and well-being.

"90% of the world's biological heritage is found in developing countries, yet the vast majority of patents are held by developed ones. Our rules for using natural resources and traditional knowledge are very ill-defined and companies exploit this legal uncertainty to use traditional knowhow. The EU must help to ensure that benefits are shared fairly, in line with its commitment to combat poverty," stressed author of the resolution Catherine Greze (Greens, FR).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical